Peripheral blood stem cells provide early engraftment, decreasing the risk of prolonged neutropenia and sepsis, with a focus on maintaining CD34 and CD3 dose of a minimum of 5 × 106/kg and 1.5 × 108/kg recipient body weight, respectively, in the infused graft.